Novartis

Novartis 1Q10

1Q Revenues: $12.1 billion (+25%)

1Q Earnings: $2.9 billion (+49%)

Comments: The Pharma division had revenues of $7.2 billion (+13%, +7% in constant currency), although top-seller Diovan was down 1% (c.c.) to $1.4 billion. Net sales from the top six emerging markets were up 38% to $1.2 bilion. Vaccine sales accounted for more than $1.0 billion in revenue growth, driven by H1N1 preparations. Sandoz (generic) revenues were up 16% (+9% c.c.) to $2.0 billion; U.S. generics and biosimilars were up 19% c.c.